Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.79 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.54 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.54 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.54 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.54 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.54 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ESRRA | P11474 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL619663 | 0.98 | MAPT (0.76) | MAPTHPGDRAB9APARP10NPC1 | |
| SCHEMBL18752059 | 0.94 | MAPT (0.70) | MAPTHPGDRAB9APARP10NPC1 | |
| SCHEMBL203697 | 0.89 | HPGD (1.00) | MAPTHPGDRAB9APARP10ALDH1A1 | |
| SCHEMBL3301210 | 0.89 | HPGD (1.00) | MAPTHPGDRAB9APARP10ALDH1A1 | |
| SCHEMBL223335 | 0.87 | MAPT (0.75) | MAPTHPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL12220509 | 0.86 | MAPT (0.59) | MAPTHPGDRAB9APARP10NPC1 | |
| SCHEMBL17198004 | 0.85 | POLB (0.67) | MAPTHPGDRAB9APARP10NPC1 | |
| Hydrochloric Acid SCHEMBL4372451 | 0.84 | MAPT (0.72) | MAPTHPGDRAB9ANPC1ALDH1A1 | |
| SCHEMBL11646587 | 0.84 | MAPT (0.72) | MAPTHPGDRAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4289450 | 0.84 | MAPT (0.72) | MAPTHPGDRAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022161556-A1 | TACRINE DERIVATIVES POSSESSING DUAL ACTIVITY AND THEIR USE | FAKULTNI NEMOCNICE HRADEC KRALOVE (CZ) | 2022-08-04 | — | — | WO | disclosed |
| EP-2755722-B1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD (IN) | 2017-05-24 | — | — | EP | disclosed |
| US-9200116-B2 | Water soluble binder composition, method of producing the same and electrode for rechargeable battery employing | SAMSUNG SDI CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9200116-B2 | Water soluble binder composition, method of producing the same and electrode for rechargeable battery employing | SAMSUNG SDI CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9018249-B2 | SGLT inhibitors | PANACEA BIOTEC LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2755722-A2 | NOVEL SGLT INHIBITORS | Panacea Biotec Ltd. (IN) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038429-A2 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD. (IN) | 2013-03-21 | — | — | WO | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5610020-A | CLEAVING TO LABEL MOLECULAR SPEICES IN ANALYTES; VOLATILE FOR DETERMINATION IN GAS PGHASE | NORTHEASTERN UNIVERSITY (US) | 1997-03-11 | — | — | US | disclosed |
| US-5604104-A | BIOLOGICAL ANALYSIS USING A CLEAVABLE LABEL CAPABLE OF VOLATILIZATION AND DETECTION IN THE VAPOR PHASE; MEDICAL DIAGNOSIS; HUMAN GENOME PROJECT; GENETIC DISORDERS | NORTHEASTERN UNIVERSITY (US) | 1997-02-18 | — | — | US | disclosed |
| US-5602273-A | WHEN CLEAVED RELEASE STABLE ELECTROPHORIC KETONES VOLATILE ENOUGH FOR DETERMINATION IN GAS PHASE | NORTHEASTERN UNIVERSITY (US) | 1997-02-11 | — | — | US | disclosed |
| US-5516931-A | AROMATIC FLUORINATED KETONES FOR CHEMICAL LABELS | NORTHEASTERN UNIVERSITY (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2180/4885HPGD 2652/4885RAB9A 1936/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | MAPT 2754/4885HPGD 2749/4885RAB9A 1400/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPT 2299/4885HPGD 2745/4885RAB9A 2093/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPT 2474/4885HPGD 2852/4885RAB9A 2639/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | MAPT 2928/4885HPGD 2546/4885RAB9A 1099/4885 |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | MAPT 65/4885HPGD 1032/4885RAB9A 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.